Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Zalfermin (NNC0194-0499) in Chinese Males
NCT05742919Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nn9500 in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum concentration-time curve from time 0 to infinity. Started Feb 2023; status: completed.
02
Drugs
nn9500
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05742919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742919.